Navigation Links
NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
Date:7/14/2011

anism, releasing from bone marrow and traveling to the damaged region of the heart following an AMI. Treatment with AMR-001 involves infusion of an active population of these cells directly into a patient’s heart via an intra-coronary catheter six to eleven days after an AMI (i.e., after the “hot (inflammatory) phase”) and as such complements the body’s natural  rescue mechanism for those cells that face hypoxic stress (i.e., oxygen deprivation) as a result of an increased workload.

Unlike competitor cell therapy products being tested for cardiac repair post-AMI, NeoStem believes AMR-001 stands alone in its ability to claim all of the following attributes:

  • a confirmed mechanism of action
  • a cGMP (current good manufacturing practices) facility
  • an established dose that exceeds the threshold of biological activity
  • use of autologous cells that have no risk of rejection and are capable of integrating and providing local support, potentially for a prolonged period of time as demonstrated in pre-clinical animal experiments
  • cells that are not expanded, thereby eliminating the potential concerns associated with such expansion
  • composition of matter, methods and processes patents with long remaining life

  • To the Company's knowledge, this is the first stem cell trial in AMI ever conducted that prospectively established a significant relationship between dose and effect. NeoStem intends to enter the clinic for the start of the Phase II trial for AMR-001 no later than the  first quarter of 2012 and to commence a Phase I study in congestive heart failure in 2012.  The enrollment of this Phase II trial is estimated to complete within 12 months from start with data read-out 6 months after the last patient is treated.

    The definitive merger agreement provides for the issuance of an aggregate of 6,821,283 shares of NeoStem common stock and warrants to purchase an aggregate o
    '/>"/>

    SOURCE NeoStem, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
    2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
    3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
    4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
    5. NeoStem Announces Warrant Exercise by Principal Shareholder
    6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
    7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
    8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
    9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
    10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
    11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2015)... TWi Pharmaceuticals, Inc. ("TWi") today announced ... with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... Inc. (individually and collectively, "Takeda") to settle and ... generic dexlansoprazole delayed release capsules for oral administration ... Abbreviated New Drug Application for TWi,s generic product ...
    (Date:4/25/2015)... -- Hospira, Inc. (NYSE: HSP ... sprach heute auf der jährlichen Konferenz der Europäischen ... London über die Bedeutung von ... für Patienten. Das Unternehmen kündigte auch ... Titel „Why extrapolation is paramount to achieving ...
    (Date:4/24/2015)... 24, 2015 Today, humanity takes a massive step ... and fat-free cronuts: 1-800 CONTACTS announces their new Apple Watch ... two taps. Two taps. New contacts. From your ... The app also features LensGauge which helps keep track of ... need to reorder. "Since our inception, we,ve been ...
    Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2
    (Date:4/27/2015)... Mirada, CA (PRWEB) April 27, 2015 ... minimally invasive treatments for nail fungi and infections. Onychomycosis, ... to affect up to 10% of adults in the ... fragility, and irregularity in thickness. , Healthpointe’s ... Institute , a branch dedicated to providing quality skincare ...
    (Date:4/27/2015)... Miami, FL (PRWEB) April 27, 2015 ... policies from arresting nonviolent drug offenders to providing drug ... by Nepr on April 8th. Several states, ... cut state costs revolving incarceration. Texas has formed community ... populace. According to The Council of State Governments ...
    (Date:4/27/2015)... April 27, 2015 Consumer Choice ... Service Providers in their respective sectors for Ottawa. We ... year’s winners; your dedication to superior service has resonated ... Canada, Consumer Choice Award gathers opinions, perceptions and expectations ... All winners have gone through a rigorous selection process ...
    (Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
    (Date:4/27/2015)... April 27, 2015 Final Cut Pro ... footage with ProTelestrator from Pixel Film Studios. A telestrator is ... sketch over a moving or still video image. Telestrators are ... analyze sports plays or incoming weather patterns. , After users ... then adjust the frame slider to control the speed of ...
    Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:2015 Ottawa Consumer Choice Award-Winners 2Health News:2015 Ottawa Consumer Choice Award-Winners 3Health News:2015 Ottawa Consumer Choice Award-Winners 4Health News:2015 Ottawa Consumer Choice Award-Winners 5Health News:2015 Ottawa Consumer Choice Award-Winners 6Health News:2015 Ottawa Consumer Choice Award-Winners 7Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2
    ... has been discovered by researchers at Seoul National University. It ... highly expressed in lung cancer cells and also that patients ... study is published on March 31 in the open-access journal ... of the world,s most common cancers and a leading cause ...
    ... cancer organizations shows rates of death in the United States from ... and 2007. The findings come from the latest Annual Report to ... also finds that the overall rate of new cancer diagnoses for ... 1 percent per year for the same period. Edward J. ...
    ... from the University of Pittsburgh and Stanford University discovered ... role in the ability of one the world,s most ... possible role of similarly errant proteins in other diseases. ... the National Academy of Sciences ( PNAS ) ...
    ... the obesity epidemic, the National Institutes of Health is ... for NIH Obesity Research. More than one-third ... percent of the nation,s children are now obese, which ... including type 2 diabetes, heart disease, high blood pressure, ...
    ... a total of $383,000 for chronic obstructive pulmonary disease ... Institute (NHLBI), part of the National Institutes of Health, ... COPD Learn More Breathe Better campaign and will be ... The contract supports community-based public health efforts to ...
    ... continues to grow. Following the successful First International ... Second International Conference on Immune Tolerance will bring ... and insights into the mechanisms and treatment of ... inflammation and cancer. This Conference is supported by ...
    Cached Medicine News:Health News:Pitt-Stanford research suggests aimless proteins crucial to disease 2Health News:New strategic plan for NIH obesity research seeks to curb epidemic 2Health News:NHLBI funds 9 organizations to improve awareness of COPD 2Health News:2nd International Conference on Immune Tolerance 2
    Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
    ... The VISULAS 690s is ... As the instrument of choice ... Visudyne clinical trials, Carl Zeiss ... legacy in laser manufacturing to ...
    The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
    Lens Loading and Folding for Multipiece & Single-Piece ACRYSOF Lens with Standard Forceps...
    Medicine Products: